Siron Clinical

Based in the Netherlands, Siron Clinical specializes in conducting complex clinical trials, focusing on orphan diseases, pediatrics, and medical devices, providing tailored solutions for biotech and pharmaceutical companies. Siron Clinical, founded in 2000 and headquartered in Breda, Netherlands, is an international contract research organization (CRO) that conducts complex clinical trials. The firm has engaged in one deal as of January 2026, when it was acquired by WEP Group Holdings Limited, a portfolio company of TJC. The founder's history is not detailed.

Siron Clinical is an international contract research organization (CRO) that specializes in conducting complex clinical trials across various therapeutic areas, including orphan diseases, pediatrics, and medical devices. The company offers a diverse range of services designed to support clinical research initiatives, including customizable Functional Service Provider (FSP) models and full-service solutions. These offerings are aimed at addressing critical challenges in the clinical trial process, such as regulatory submissions, quality assurance, and clinical monitoring, facilitating efficient and effective trials tailored to specific client needs. Siron Clinical primarily serves biotech and pharmaceutical companies, as well as medical device manufacturers, focusing on the European market, where compliance with local regulatory requirements is essential.

They have established a reputation for providing reliable support to clients looking to navigate the complexities of clinical trials in various European countries. Siron Clinical generates revenue through structured partnerships with its clients, primarily engaging in B2B transactions. The company operates on a service-based model, where clients pay for specific services such as project management, clinical monitoring, and quality assurance. This transactional structure allows clients to choose between customizable FSP arrangements or comprehensive full-service contracts, enabling flexibility in how they engage with the firm.

The pricing plans are designed to reflect the specialized nature of the services offered, ensuring that clients receive tailored support that meets their regulatory and operational requirements in the clinical trial landscape. The firm’s revenue is closely tied to the successful execution of clinical trials, reinforcing the importance of their expertise and service quality in driving client satisfaction and retention. In January 2026, WEP Group Holdings Limited acquired Siron Clinical, facilitating the expansion of its global footprint. The acquisition will support Siron Clinical's strategy to enhance its service offerings and geographical reach, although specific new products or markets targeted for future expansion have not been disclosed.